About ASHP Summer Meetings
The ASHP Summer Meetings & Exhibition ↗ is held each June and serves as the governance and practice-focused complement to the larger ASHP Midyear Clinical Meeting in December. The 2027 edition takes place at the Colorado Convention Center in Denver — a venue well-suited to the 5,000–7,000 pharmacy professionals expected to attend.
The Summer Meeting is distinctive in hosting the ASHP House of Delegates ↗, the official governing body of ASHP, where elected representatives vote on policy statements and therapeutic guidelines that shape pharmacy practice nationally. It also provides a focused platform for ambulatory care, pharmacy management, and health policy education.
2027 Programme Tracks
House of Delegates & Governance
Policy votes, ASHP governance, therapeutic guideline resolutions, and advocacy priorities for the coming year.
Ambulatory & Outpatient Care
Collaborative practice agreements, pharmacist-led chronic disease management, transitions of care, and medication reconciliation.
Drug Policy & Formulary
Evidence-based formulary management, drug shortage preparedness, 340B programme updates, and pharmacy benefit design.
Pharmacy Practice Models
Innovative practice model implementation, pharmacist provider status, value demonstration, and workforce pipeline.
Quality & Medication Safety
Medication error prevention, ISMP high-alert drug protocols, BCMA implementation, and Joint Commission readiness.
Education & Residency Development
ASHP residency accreditation updates, preceptor development, PharmD curriculum changes, and postgraduate training standards.
Key Policy Areas — 2027
The ASHP House of Delegates at the 2027 Summer Meeting is expected to address several major policy areas including pharmacist provider status recognition under Medicare Part B, antimicrobial stewardship programme requirements in outpatient settings, and updated policy on medication error reporting and prevention. ASHP's advocacy team also coordinates with the Centers for Medicare & Medicaid Services (CMS) ↗ on pharmacist reimbursement models.
| Policy area | Background | Key stakeholder |
|---|---|---|
| Pharmacist provider status | Medicare recognition for pharmacist services under Part B; enables direct billing for MTM, chronic disease management | CMS, APhA, ASHP |
| Antimicrobial stewardship | Outpatient ASP requirements, antibiotic prescribing guidelines, pharmacist roles in community ASP | CDC, IDSA, ASHP |
| Drug shortages | Supply chain resilience policy, DSCSA compliance, shortage communication standards | FDA, ASHP, GPOs |
| Biosimilar substitution | State pharmacy law alignment with FDA interchangeability, pharmacist counselling requirements | State BOP, FDA, NABP |
| Opioid stewardship | Naloxone co-prescribing, opioid MME limits, PDMP use, pharmacy-based harm reduction | DEA, CDC, SAMHSA |